erb-B2 as a Therapeutic Target
Trastuzumab is a humanized monoclonal antibody that targets the type 1 tyrosine kinase receptor erb-B2 and has demonstrated survival benefit when used in combination with chemotherapy in the treatment of metastatic, HER2 overexpressing breast cancer. This chapter reviews the history of the development of trastuzumab including the biology of HER signaling, the technical issues of antibody “humanization,” the diagnostic challenges in developing “targeted” therapeutic agents, and the clinical data that led to the approval of this agent for patients with HER2 overexpressing breast cancer.
Key WordsBreast cancer HER2 erb-B2 trastuzumab monoclonal antibody targeted therapy
Unable to display preview. Download preview PDF.
- 10.Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;7:1049–1056.Google Scholar
- 21.Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p 185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–2671.PubMedGoogle Scholar
- 24.Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.PubMedGoogle Scholar
- 34.“PathVysion” HER-2 DNA Probe Kit package instructions. Vysis Inc., Downers Grove, IL, 2000.Google Scholar